FDA Approves Wider Use Visudyne
QLT, Inc. and Ciba Vision Corporation have been given priority-review status from the Food and Drug Administration (FDA) for their application to expand therapy involving their blindness drug Visudyne to treatment of a range of eye diseases. Among other things, the companies are seeking permission to use Visudyne to treat certain conditions that can cause blindness in younger people. Currently, the two companies have US marketing approval for its use to treat only certain forms of age-related macular degeneration, the leading cause of blindness in people over 50 years old. For more information, visit www.fda.org.
Point-of-Care Engagement in Long-Term Care Decreasing Infections
November 26th 2024Get Well’s digital patient engagement platform decreases hospital-acquired infection rates by 31%, improves patient education, and fosters involvement in personalized care plans through real-time interaction tools.
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.
